Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK08954 in KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma
NCT07303465Phase 2Recruiting
- Sponsor
- Ranok Therapeutics
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 2, open-label trial of RNK08954 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Ranok Therapeutics. Primary endpoint: Progression-Free Survival at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
RNK08954
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07303465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303465.